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A total of 20 eluates were performed on the un- 
treated absorbing red cells. Only one yielded an anti- 
LW sup(a) using the digitonin acid elution method (Table 2) .  
The eluted anti-LW sup(a) reacted with LISS and ficin-treated 
RBCs by IAT. 
A total of 17 elution procedures (ten ether, five 
digitonin, and two chloroform) were used on the red 
cells from 11 patients with autoanti-LW sup(a) or -LWT sup(ab). 
Two ether eluates contained anti-LW (Table 3) .  
Discussion 
Elutions are useful in identification of antibodies 
from serums containing multiple specificities, confir- 
mation of antibody specificity, preparation of typing 
sera, confirmation of weak antigens on red cells, iden- 
tification of antibodies causing hemolytic disease of 
the newborn, identification of antibodies that have 
caused transfusion reactions, and investigation of an- 
tibodies from patients with acquired hemolytic 
anemia. sup(3) 
Antibody sensitization occurred as evidenced by the 
positive DAB on the absorbing cells tested prior to elu- 
tion. However, only three LW antibodies were 
recovered in the 37 eluates prepared in this study, one 
in digitonin acid and two in ether. The low recovery 
rate may be due to the low-affinity of LW antibodies 
for corresponding antigen-positive RBCs as suggested 
by the relatively high titer of the adsorbed serums. The 
low recovery rate may also he due to serological inac- 
tivation of antibody by these elution techniques. 
Conventional adsorption and elution techniques may 
not be appropriate for the serologic study of LW 
antibodies. 
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A REAGENT FOR THE CONVERSION 
OF CITRATED OR EDTA PLASMA TO 
SERUM 
Robert J. Eckrich 
Introduction 
Although serum or plasma can be used for pre- 
transfusion testing, many blood bank technologists 
prefer to use serum. Small fibrin clots, difficult to 
distinguish from agglutinates, may form when plasma 
is used. High levels of fibrinogen in some plasma 
samples can cause rouleaux formation. The activity 
of certain complement-binding antibodies may not he 
evident in plasma because anticoagulants such as citrate 
or ethylenediamine tetraacetic acid (EDTA) chelate 
calcium and magnesium and thus inhibit complement 
activation. Plasma is not suitable for use in the direct 
microcapillary testing method. 
This report describes a reagent that rapidly converts 
citrated or EDTA-anticoagulated plasma to serum. The 
reagent is inexpensive and is stable at room tempera- 
ture. After the conversion, the activity of complement 
is restored while the reactivity of blood group anti- 
bodies is not diminished. This reagent is similar 
in action to Re/coagulan* a commercial diagnostic 
reagent no longer in production. sup(2) 
Materials and Methods 
Conversion reagent 
The reagent contains 10 percent CaCI sub(2)•2, H sub(2)O, 1 
percent MgCI sub(2), 6 H sub(2)O, and 50 mg/mL kaolin (colloidal 
'Clinton Laboratories, formerly of Santa Monica, CA 
36 
hydrated aluminum silicate) in aqueous suspension. 
The reagent suspension is mixed by inversion im- 
mediately before use and is added to citrated or 
EDTA-anticoagulated plasma in a 1:20 ratio (vol/vol). 
The mixture is incubated in a glass test tube at 37°C 
until a firm clot has formed. Serum is expressed from 
the clot with a wooden applicator stick and centri- 
fuged to remove any particulate matter. 
Large volumes of plasma recovered from hema- 
pheresis or component salvage can he clotted in the 
bag by addition of 1 mL of reagent per 100 mL of 
plasma using a sampling site coupler, followed by in- 
cubation at 37°C until clot formation is observed. The 
fibrin clot is then allowed to retract at 4°C overnight 
before compressing the bag to express as much serum 
as possible. A reagent-to-plasma ratio of 1:100 can be 
used for mixtures incubated at 4°C overnight but not 
for those incubated less than an hour. 
Plasma samples 
Plasma samples used for conversion to serum in this 
study were recovered from donor units or from EDTA- 
anticoagulated patient specimens sent to the reference 
laboratory for referral studies. 
Studies on coagulation time 
Aliquots of 1, 2, 3, 4 ,  and 5 mL of plasma from a 
single-donor unit were placed in glass tubes of various 
sizes and prewarmed to 37°C. Reagent was added in 
a 1:20 ratio, the aliquots mixed, and the tubes observed 
every 30 seconds until clot formation. Control tubes 
were run in parallel using 10 percent calcium chloride 
in place of the reagent. 
In a separate experiment, 5 mL aliquots of citrated 
plasma from 13 different donor units containing ir- 
regular antibody were converted in the same manner 
except that the plasma was not prewarmed. Aliquots 
were then used for the studies on antibody reactivity 
and complement activity described below. 
The time needed to clot EDTA-anticoagulated plasma 
was similarly studied using 2 mL aliquots of plasma 
from nine different samples. 
Studies on antibody reactivity and complement 
activity 
Titration studies were performed in parallel on the 
aliquots of converted plasma with irregular antibody 
described above and on unconverted plasma using 
standard blood bank methods3 and scored according 
to Marsh. sup(4) The complement activity of the converted 
plasmas was studied using the low-ionic strength 
method of Garratty and Petz sup(5) for preparing C3/C4 
coated RBCs. 
Results 
Studies on coagulation time 
The prewarmed aliquots of citrated plasma from the 
same donor plus conversion reagent all contained firm 
clots within three min, regardless of the volume of 
plasma or size of glass tube used. The control aliquots, 
run in parallel with 10 percent CaCI sub(2)•2 H sub(2)O in place 
of the conversion reagent, clotted within 10-13 min. 
The 5 mL aliquots of citrated plasma that contained 
unexpected antibodies and that were not prewarmed 
clotted within 4-10 min. The time needed to clot the 
2 mL aliquots of EDTA-anticoagulated plasma, treated 
in this same manner, ranged from 20-31 min. 
Studies on antibody reactivity and 
complement activity 
The reactivity of the blood group antibodies in the 
13 citrated plasmas was essentially the same after con- 
version as before conversion (Table 1). In all 
converted plasmas tested, complement could be 
activated to coat cells with C3 and C4. 
Discussion 
The principle behind the action of this reagent is 
similar to that used in the original activated partial 
thromboplastin method of Proctor and Rappaport, sup(6) 
except that a platelet substitute is omitted. Kaolin is 
a potent activator of coagulation Factor XII (Hageman 
Factor). By including kaolin in the reagent, citrated 
plasma can clot more quickly than if calcium chloride 
alone is used. Kaolin also appears to reduce the 
variability in clotting time, which is ascribed to the 
nature of glass contact. The longer time needed to 
convert EDTA-anticoagulated plasma to serum is 
presumably because EDTA is a more powerful chelating 
agent than citrate.' 
This conversion method has several advantages over 
conventional methods. Because the reagent contains 
electrolytes only, it is not likely to be contaminated 
by bacteria and can be stored at room temperature. The 
addition of magnesium ion in the form of magnesium 
chloride to the reagent restores the complement- 
binding activity, which simple recalcification will not 
Table 1. Antibody reactivity in anticoagulated 
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accomplish. Finally, because it contains no biological 
material, the reagent cannot introduce unsuspected an- 
tibodies that could cause a positive reaction. In 1985, 
Bliznik sup(8) and Dolor and Kastetter sup(9) described some 
human thrombin preparations containing anti-D that 
were used to expedite the clotting of plasma. This 
unexpected antibody caused positive direct and in- 
direct antiglobulin tests. 
When the raw materials are purchased in 500 g 
quantities, the cost of making this reagent is 31 cents 
per 100 mL, substantially less than the cost of a similar 
quantity of thrombin. The use of this reagent 
represents a simple, inexpensive, rapid method for 
clotting anticoagulated plasma and restoring its com- 
plement activity. The reactivity of antibodies of 11 
blood group specificities was not decreased by the 
presence of this reagent in plasma. 
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Serums containing an antibody to one low-incidence 
antigen will often contain antibodies to other low- 
incidence antigens. One such example of multiple 
specificities was reported by Contreras et al, sup(1) who 
studied a serum containing antibodies to Mi", Vw, Mt sup(a), 
Bp sup(a), Gf, Go sup(a), Mo sup(a), Or, Tr sup(a), Wr sup(a), Pt sup(a), Rh32, and Rh37. 
In the Rh system, cross-reactivity has been reported 
between low-incidence antigens Go sup(a), Rh32, and Evans 
and between Rh32 and D sup(W).2 This is a report of a case 
of anti-D sup(w) and -Rh32 in a patient's serum that tested 
as separate antibodies. 
Case History 
A blood sample from a thirty-nine-year-old black 
man with chronic renal failure was submitted to our 
reference laboratory for antibody identification. The 
referring hospital transfusion service bad detected an 
antibody directed against one of two antibody screen- 
ing cells. Additional panel cells and crossmatches were 
tested and all were compatible. These findings sug- 
gested the presence of an antibody to a low-incidence 
antigen. 
The patient bad received multiple transfusions as 
the result of chronic renal failure, but the unexpected 
antibody had not been previously detected. 
Materials and Methods 
Red cell typings were performed by standard 
techniques3 using commercial reagents and single- 
donor antisera (including anti-Rh32) obtained from 
Scarf and Transferase.* D sup(W) testing was done by Ortho 
(Raritan, NJ). The patient's serum was tested with 
examples of Rh:32 and D sup(W) positive cells selected from 
commercial panels (Cooper Biomedical, Malvern, PA, 
and Immucor Inc., Norcross, GA) and also rare donor 
cells obtained as Scarf or Transferase samples. The 
referring hospital's screening cells were from Ortho 
Diagnostic Systems' Selectogen Reagent Red Blood 
Cells, Raritan, NJ. 
The antibody detection test system of the referring 
transfusion service consisted of the addition of 
albumin to the test system and readings at immediate 
spin (IS), 37°C and indirect antiglobulin test (IAT). Our 
reference laboratory used a low-ionic strength solu- 
tion (LISS) at room temperature, 37°C and IAT. 
Micromethods were used to perform adsorption- 
elution studies4 (see Appendix). The indirect 
antiglobulin test using the microcapillary method was 
used in some cases to test serum or eluates.5 
Results of Serological Testing 
The patient's red blood cells typed as group B 
Rh-positive. The hospital transfusion service had 
detected an antibody that failed to react at IS but did 
produce 1 + agglutination at the albumin 37°C phase 
and 2 + at IAT with one of the two Ortho antibody 
screening cells (Screening Cell II). Commercial panels 
and crossmatches were negative. 
We tested the patient's serum with the same screen- 
ing cells using a LISS/IAT method. Screening Cell 11 
reacted but only after conversion to the IAT. This reac- 
tivity remained after DTT-treatment of the serum, 
suggesting an IgG antibody. 
We then tested the patient's serum against 58 red 
'Scarf is an internatioinal exchange progm Of serum. cells, and mare fluids. 
Transferase i s  a similar program for American Red Cross Rlood Services. 
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